Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer’s disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer’s disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.
Perelman School of Medicine
Arthur Caplan of the School of Medicine comments on reality in a medical-sitcom script.
Edna Foa of the School of Medicine discusses the mental trauma the rescued Chilean miners might face.
How a T cell decides to make protein X, Y, or Z can have profound effects for fighting foreign invaders or staving off dire autoimmune reactions. Researchers at the University of Pennsylvania School of Medicine have identified the steps that control how different forms of an immune cell protein called CD45, which is critical for activating the immune system when faced with pathogens, are controlled in the arc of a body’s immune response.
The University of Pennsylvania’s Abramson Cancer Center has been rated as “exceptional” by the National Cancer Institute (NCI) during a competitive research funding review by the government agency.
Four professors from the University of Pennsylvania School of Medicine have been elected members of the Institute of Medicine (IOM), one of the nation's highest honors in biomedicine. Three of the four new inductees are women.
The new members bring Penn's total to 76, out of a total active membership of 1,649.
Overall, the IOM named 65 new members this year and foreign associates.
PHILADELPHIA –- The University of Pennsylvania’s Center for Technology Transfer has been honored with a Deal of Distinction Award by the Licensing Executive Society (USA and Canada) Inc.
The award was given for a collaborative research agreement forged earlier this year by Penn and pharmaceutical company Astra Zeneca that will make use of academic and private-industry resources to generate new Alzheimer’s disease drug candidates for clinical development.
Heart muscle cells do not normally replicate in adult tissue, but multiply with abandon during development. This is why the loss of heart muscle after a heart attack is so dire—you can’t grow enough new heart muscle to make up for the loss.